• 1
    Bacon B, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 2
    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 3
    Ghosal A, Yuan Y, Tong W, Su A, Gu C, Chowdhury SK, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a HCV protease inhibitor. Drug Metab Dispos 2011; 39: 510-521.
  • 4
    Chu X, Cai X, Cui D, Evers R, Green MD, Ghosal A, et al. In vitro assessment of drug-drug interaction potential of boceprevir as an inhibitor and inducer of drug metabolizing enzymes and transporters [Abstract]. HEPATOLOGY 2011; 54( Suppl. 4): 547A.
  • 5
    Berenguer M. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005; 9: 579-600.
  • 6
    Prograf tacrolimus capsules, tacrolimus injection (for intravenous infusion only) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; 2006.
  • 7
    Neoral soft gelatin capsules (cyclosporine capsules, USP) modified Neoral oral solution (cyclosporine oral solution, USP) modified. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
  • 8
    Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
  • 9
    Bednarczyk D. Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3. Anal Biochem 2010; 405: 50-58.
  • 10
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. HEPATOLOGY 2011; 54: 20-27.
  • 11
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
  • 12
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplant 2002; 8: 350-355.
  • 13
    Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
  • 14
    Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin. Presented at: 16th Annual Meeting of HEP DART; December 4-8, 2011; Koloa, Hawaii.
  • 15
    Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Presented at: 16th Annual Meeting of HEP DART; December 4-8, 2011; Koloa, Hawaii.
  • 16
    Victrelis (boceprevir) capsules [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2011.
  • 17
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transplant 2004; 10: 1258-1262.
  • 18
    Oo YH, Dudley T, Nightingale P, Haydon G, Mutimer D. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transplant 2008; 14: 81-87.
  • 19
    Jochum C, Beste M, Penndorf V, Farahani MS, Testa G, Nadalin S, et al. Quantitative liver function tests in donors and recipients of living donor liver transplantation. Liver Transplant 2006; 12: 544-549.
  • 20
    Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941-952.
  • 21
    Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transplant 2002; 8: 841-845.
  • 22
    Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant 2004; 10: 939-944.
  • 23
    Mantry PS, Hassett MS, Weinstein J, Mubarak A, Madani B, Nazario H, et al. Triple therapy using telaprevir in the treatment of hepatitis C recurrence after liver transplantation: an early single center experience. Presented at: 16th Annual Meeting of HEP DART; December 4-8, 2011; Koloa, Hawaii.
  • 24
    Rebetol (ribavirin UPS) capsules, oral solution [prescribing information]. Kenilworth, NJ: Schering Plough; 2009.
  • 25
    PegIntron (peginterferon alfa-2b) injection [prescribing information]. Kenilworth, NJ: Schering Plough; 2009.